香港生物医药股今日继续调整，其中乐普生物-B（02157）盘中大跌6.14%，引发市场关注。
据市场分析，此轮生物医药股下跌与香港金融管理局的政策举措密切相关。香港金管局持续回收港元流动性，导致一个月HIBOR上升至两个月高位2.57%，港美利差迅速收窄至1.76%。这一举措直接影响了企业融资成本和投资者的保证金借贷成本，可能降低投资者使用杠杆的意愿。
分析人士指出，对流动性较为敏感的生物医药股、尚未盈利的科技股以及本地地产股可能面临较大的调整压力。除乐普生物-B外，同源康医药-B、翰森制药、科伦博泰生物-B等多只生物医药股今日均出现不同程度的下跌。投资者需密切关注后市走势，谨慎评估相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.